ACAD Q4 2019 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$98M+65.1% YoY

Gross Profit

$93M94.6% margin

Operating Income

-$56M-57.4% margin

Net Income

-$53M-53.9% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+4.0%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$783M

Total Liabilities

$84M

Stockholders' Equity

$699M

Cash & Equivalents

$190M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$98M	$60M	+65.1%
Gross Profit	$93M	$55M	+68.5%
Operating Income	-$56M	-$67M	+16.2%
Net Income	-$53M	-$65M	+19.0%